Biovinate Use In Pregnancy & Lactation

Use in Pregnancy: There is evidence that carboplatin can cause fetal toxicity when administered to pregnant women. It has been shown to be embryotoxic and teratogenic in rats receiving it during organogenesis. To date, there are no adequate or controlled studies using carboplatin to establish its safety in pregnant women. Women of childbearing potential should be advised to avoid becoming pregnant. If the patient becomes pregnant while taking carboplatin or if the drug is administered during pregnancy, the patient should be informed of the potential harm to the fetus.
Use in Lactation: It is not known whether carboplatin is excreted in human milk. Because there is a possibility of toxicity in nursing infants if the drug were distributed into milk, breastfeeding should be discontinued during carboplatin therapy.